AZD5363 inhibits inflammatory synergy between interleukin-17 and insulin/insulin-like growth factor 1

AZD5363 inhibits inflammatory synergy between interleukin-17 and insulin/insulin-like growth factor 1

In the United States, one third of population is affected by obesity and almost 29 million people are suffering from type 2 diabetes. Obese people have elevated serum levels of insulin, insulin-like growth factor 1 (IGF1) and interleukin-17 (IL-17). Insulin and IGF1 are known to enhance IL-17-induce...

Full description

Bibliographic Details
Main Authors: Chong eChen, Qiuyang eZhang, Sen eLiu, Mark eLambrechts, Yine eQu, Zongbing eYou
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-12-01
Series:Frontiers in Oncology
Subjects:
Inflammation
Insulin
prostate cancer
IGF1
IL-17
obesity.
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00343/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00343/full

Similar Items